Piper Jaffray Cos. set a $106.00 target price on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a report released on Thursday morning. The firm currently has a a buy rating on the biopharmaceutical company’s stock.
A number of other brokerages have also weighed in on ALNY. Needham & Company LLC reaffirmed a buy rating and set a $152.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 5th. Cowen and Company reaffirmed a buy rating and set a $150.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Jefferies Group set a $86.00 target price on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, September 28th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 28th. They set a neutral rating and a $74.00 target price on the stock. Finally, Goldman Sachs Group Inc. reaffirmed a neutral rating and set a $65.00 target price (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 10th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of Buy and a consensus price target of $80.88.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.52 on Thursday. Alnylam Pharmaceuticals has a 1-year low of $33.16 and a 1-year high of $110.75. The stock’s market cap is $3.04 billion. The firm has a 50-day moving average of $69.62 and a 200 day moving average of $65.95.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.85) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Slate Path Capital LP boosted its stake in shares of Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares in the last quarter. State Street Corp raised its position in Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock worth $121,553,000 after buying an additional 262,783 shares during the last quarter. Bridger Management LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter worth $50,041,000. Schroder Investment Management Group raised its position in Alnylam Pharmaceuticals by 235.0% in the second quarter. Schroder Investment Management Group now owns 18,592 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 13,042 shares during the last quarter. Finally, Turner Investments L.P. purchased a new position in Alnylam Pharmaceuticals during the second quarter worth $575,000. 85.96% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.